Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Antiviral therapy for chronic HBV infection was associated with a reduced risk for HCC

A study in May's issue of Clinical Gastroenterology & Hepatology evaluates the use of antiviral therapy for chronic Hepatitis B virus infection and development of hepatocellular carcinoma in a US population.

News image

Antiviral therapy could reduce the risk of hepatocellular carcinoma (HCC) among persons with chronic hepatitis B virus (HBV) infection.

Dr Stuart Gordon and colleagues evaluated the relationship between therapy for chronic HBV infection, and HCC incidence using data from a longitudinal study of patients at 4 US healthcare centers.

The research team analyzed electronic health records of 2671 adult participants in the Chronic Hepatitis Cohort Study who were diagnosed with chronic HBV infection from 1992 through 2011.

Data analyzed were collected for a median of 5 years.

Propensity-score adjustment was used to reduce bias, and Cox regression was used to estimate the relationship between antiviral treatment and HCC.

The primary outcome was time to event of HCC incidence.

3% developed HCC during follow-up period
Clinical Gastroenterology & Hepatology

Of study subjects, the team found that 3% developed HCC during follow-up period.

Of these, 20 cases were among the 820 patients with a history of antiviral HBV therapy, and 47 cases among the 1851 untreated patients.

The researchers found that patients who received antiviral therapy had a lower risk of HCC than those who did not receive antiviral therapy, after adjusting for abnormal level of alanine aminotransferase.

In a subgroup analysis, the team noted that antiviral treatment was associated with a lower risk of HCC after adjusting for serum markers of cirrhosis.

In a separate subgroup analysis of patients with available data on HBV DNA viral load, treated patients with viral loads >20,000 IU/mL had a significantly lower risk of HCC than untreated patients with viral loads >20,000 IU/mL.

Dr Gordon's team commented, "In a large geographically, clinically, and racially diverse US cohort, antiviral therapy for chronic HBV infection was associated with a reduced risk for HCC."

Clin Gastroenterol Hepatol 2014: 12(5): 885893
01 May 2014

Go to top of page Email this page Email this page to a colleague

 25 May 2015

Advanced search
 25 May 2015 
Colorectal cancer screening
 25 May 2015 
Saccharomyces boulardii and H. pylori
 25 May 2015 
Risk of GI bleeds with NSAIDs
 22 May 2015 
Colonoscopy screening for colorectal cancer
 22 May 2015 
Treatment with anti-integrin antibodies in IBD
 22 May 2015 
Care of patients with GERD
 21 May 2015 
Lymphoma in IBD
 21 May 2015 
Serrated polyps and colorectal cancer
 21 May 2015 
Imaging for hepatocellular carcinoma
 20 May 2015 
Surveillance in long-segment Barrett's
 20 May 2015 
Pancreatic neuroendocrine tumors
 20 May 2015 
Refractory metastatic colorectal cancer
 19 May 2015 
Metabolic syndrome and Barrett's
 19 May 2015 
PPIs and cryptogenic liver abscess
 19 May 2015 
Anti-integrin antibodies in IBD
 18 May 2015 
ESPGHAN celiac guidelines
 18 May 2015 
HLA haplotypes and primary sclerosing cholangitis
 18 May 2015 
Safety of PPI
 15 May 2015 
Microscopic colitis risk with PPIs/NSAIDs
 15 May 2015 
Management of nonhospitalized ulcerative colitis
 15 May 2015 
Diabetes and infections in IBD with immunomodulation
 14 May 2015 
Diagnosis of spontaneous bacterial peritonitis
 14 May 2015 
Mortality in US patients with cirrhosis
 14 May 2015 
Radiation exposure during ERCP
 13 May 2015 
Predictors of IBD
 13 May 2015 
Psychological distress and liver disease mortality
 13 May 2015 
Hypnotherapy in IBS/IBD
 12 May 2015 
Bleeding in NSAID users with H.pylori
 12 May 2015 
Capsule colonoscopy detects colorectal polyps
 12 May 2015 
Anti-TNF biologics in acute severe ulcerative colitis
 11 May 2015 
Management of Barrett's esophagus
 11 May 2015 
Marker to detect recurrence of Crohn's
 11 May 2015 
Thalidomide for IBD
 08 May 2015 
Surveillance colonoscopy in colorectal cancer
 08 May 2015 
HCV treatment with compensated cirrhosis
 08 May 2015 
Medical management of Crohn's
 07 May 2015 
Surgical complications in ulcerative colitis
 07 May 2015 
Combination therapy for noncirrhostic patients
 07 May 2015 
Anxiety and new-onset dyspepsia
 06 May 2015 
PPIs and spontaneous bacterial peritonitis
 06 May 2015 
Infant feeding and celiac disease
 06 May 2015 
Preventing recurrent C. diff infection
 05 May 2015 
Fatigue in primary sclerosing cholangitis
 05 May 2015 
Annual CT scans after esophagectomy for cancer
 05 May 2015 
Prevalence of eosinophilic esophagitis
 04 May 2015 
Stress resilience and peptic ulcer disease
 04 May 2015 
Endoscope storage and microbial colonization
 04 May 2015 
Menarche and NAFLD
 01 May 2015 
Sleep and physical activity measured in Crohn's
 01 May 2015 
NAFLD progression from steatosis to fibrosing-steatohepatitis
 01 May 2015 
Dietary supplement hepatotoxicity
 30 April 2015 
Risk factors for primary sclerosing cholangitis
 30 April 2015 
Botulinum toxin A for the treatment of obesity
 30 April 2015 
Neoadjuvant chemoradiotherapy for esophageal cancer
 29 April 2015 
Liver enzyme elevations after anti-TNF therapy in IBD

 29 April 2015 
Hepatocellular carcinoma surveillance in HBV
 29 April 2015 
Response to sorafenib in hepatocellular carcinoma
 28 April 2015 
Risk factors of hepatocellular carcinoma
 28 April 2015 
Clinical outcomes after esophagectomy
 28 April 2015 
Alcohol drinking and risk of liver cirrhosis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us